Evidence map›Paper›PMID 34497849›Full record

ArticleBioMed research international2021

Assessment of Serum sRANKL, sRANKL/OPG Ratio, and Other Bone Turnover Markers with the Estimated 10-Year Risk of Major and Hip Osteoporotic Fractures in Rheumatoid Arthritis: A Cross-Sectional Study.

C A Nava-Valdivia, J M Ponce-Guarneros, A M Saldaña-Cruz, E G Corona-Sanchez, M Ramirez-Villafaña, E E Perez-Guerrero, J D Murillo-Saich, B Contreras-Haro, M L Vazquez-Villegas, F Gonzalez-Ponce and 10 more

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Mechanisms of Systemic Osteoporosis in Rheumatoid Arthritis.International journal of molecular sciences · 2022
    Review
  8. Organokines in Rheumatoid Arthritis: A Critical Review.International journal of molecular sciences · 2022
    Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 2 countries.

C A Nava-ValdiviaDepartamento de Microbiología y Patología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico.
J M Ponce-GuarnerosUnidad Médica Familiar 97, Instituto Mexicano del Seguro Social (IMSS), 46470 Magdalena, JAL, Mexico.
A M Saldaña-CruzInstituto de Terapéutica Experimental y Clínica (INTEC), Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico.
E G Corona-SanchezDepartamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico.
M Ramirez-VillafañaDepartamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico.
E E Perez-GuerreroInstituto de Investigación en Ciencias Biomédicas (IICB), Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico.
J D Murillo-SaichDepartment of Medicine, School of Medicine, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA.
B Contreras-HaroDepartamento de Ciencias Biomédicas, Centro Universitario de Tonalá, Universidad de Guadalajara, 45425 Tonalá, JAL, Mexico.
M L Vazquez-VillegasPrograma de Doctorado en Ciencias de la Salud Pública, Departamento de Salud Pública, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico.
F Gonzalez-PoncePrograma de Doctorado en Farmacología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico.
D Bonilla-LaraPrograma de Doctorado en Farmacología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico.
H Jacobo-CuevasPrograma de Doctorado en Farmacología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico.
J D Centeno-ValadezDepartamento de Reumatología, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, 44329 Guadalajara, JAL, Mexico.
G Echeverria-GonzalezDepartamento de Reumatología, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, 44329 Guadalajara, JAL, Mexico.
S Cerpa-CruzDivisión de Reumatología, Hospital Civil de Guadalajara "Fray Antonio Alcalde", 44280, Guadalajara, JAL, Mexico.
M F Alcaraz-LopezDepartamento de Medicina Interna-Reumatología, Hospital General Regional 46, IMSS, 44910 Guadalajara, JAL, Mexico.
E G Cardona-MuñozDepartamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico.
M Salazar-ParamoPrograma de Doctorado en Farmacología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico.
L Gonzalez-LopezPrograma de Doctorado en Ciencias de la Salud Pública, Departamento de Salud Pública, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico.ORCID https://orcid.org/0000-0002-6517-6344
J I Gamez-NavaPrograma de Doctorado en Ciencias de la Salud Pública, Departamento de Salud Pública, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico.ORCID https://orcid.org/0000-0003-0001-3787
Universidad de Guadalajara · MXMexican Social Security Institute · MXHospital Civil de Guadalajara · MXUniversity of California San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFracture risk assessment tool (FRAX) index was developed for estimating of the 10-year risk of major or hip osteoporotic fracture. To date, there is insufficient information regarding the correlation between FRAX and serum bone turnover markers (BTMs), such as soluble ligand of receptor activator of nuclear factor-

methodsCross-sectional study included 156 postmenopausal women with RA. Bone mineral density (BMD) was measured at lumbar spine (L1-L4) and total hip using dual-energy X-ray absorptiometry (DXA). RA patients were divided into (A) RA + osteoporosis and (B) RA without osteoporosis. FRAX scores were calculated including the total hip BMD. Serum sRANKL, OPG, DKK-1, and SOST levels were measured by ELISA. Pearson tests were used for assessing the correlation between serum levels of these molecules and FRAX scores in RA.

resultsThe RA + osteoporosis group had elevated sRANKL levels (

conclusionHigh sRANKL levels and sRANKL/OPG ratio can be useful to detect a subgroup of RA patients who has an increased 10-year risk of major and hip osteoporotic fractures.

Indexed as

Arthritis, RheumatoidBiomarkersBone DensityBone RemodelingCross-Sectional StudiesFemaleHumansMiddle AgedOsteoporosisOsteoporotic FracturesOsteoprotegerinPostmenopausePrognosisRANK LigandBiomarkersOsteoprotegerinRANK LigandTNFRSF11B protein, humanTNFSF11 protein, human

Identifiers

PMID34497849
PMCPMC8421166
OpenAlexW3198164280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.